Dyax Corp. Director Thomas L. Kempner Sells 113,755 Shares (DYAX)
Dyax Corp. (NASDAQ:DYAX) Director Thomas L. Kempner sold 113,755 shares of the company’s stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $9.67, for a total transaction of $1,100,010.85. Following the sale, the director now directly owns 28,041 shares in the company, valued at approximately $271,156. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of research firms have recently commented on DYAX. Analysts at Leerink Swann raised their price target on shares of Dyax Corp. from $7.00 to $8.00 in a research note on Wednesday, July 30th. Analysts at Bank of America reiterated a “positive” rating on shares of Dyax Corp. in a research note on Wednesday, May 28th. Five equities research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of $12.14.
Dyax Corp. (NASDAQ:DYAX) traded down 2.70% during mid-day trading on Thursday, hitting $9.545. 603,754 shares of the company’s stock traded hands. Dyax Corp. has a one year low of $4.13 and a one year high of $10.99. The stock has a 50-day moving average of $9.19 and a 200-day moving average of $8.53. The company’s market cap is $1.300 billion.
Dyax Corp. (NASDAQ:DYAX) last posted its quarterly earnings results on Tuesday, July 29th. The company reported ($0.02) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.05) by $0.03. The company had revenue of $19.59 million for the quarter, compared to the consensus estimate of $14.13 million. During the same quarter last year, the company posted $0.08 earnings per share. Dyax Corp.’s revenue was up 72.9% compared to the same quarter last year. On average, analysts predict that Dyax Corp. will post $-0.19 earnings per share for the current fiscal year.
Dyax Corp. (NASDAQ:DYAX), is a biopharmaceutical company with two business elements: Angioedema Franchise and Phage Display Licensing and Funded Research Program.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.